![These highlights do not include all the information needed to use EVEROLIMUS TABLETS safely and effectively. See full prescribing information for EVEROLIMUS TABLETS. EVEROLIMUS tablets, for oral useInitial U.S. Approval: 2009 These highlights do not include all the information needed to use EVEROLIMUS TABLETS safely and effectively. See full prescribing information for EVEROLIMUS TABLETS. EVEROLIMUS tablets, for oral useInitial U.S. Approval: 2009](https://dailymed.nlm.nih.gov/dailymed/image.cfm?name=image-01.jpg&id=598237)
These highlights do not include all the information needed to use EVEROLIMUS TABLETS safely and effectively. See full prescribing information for EVEROLIMUS TABLETS. EVEROLIMUS tablets, for oral useInitial U.S. Approval: 2009
![Safety and pharmacokinetics of paclitaxel and the oral mTOR inhibitor everolimus in advanced solid tumours | British Journal of Cancer Safety and pharmacokinetics of paclitaxel and the oral mTOR inhibitor everolimus in advanced solid tumours | British Journal of Cancer](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fsj.bjc.6604851/MediaObjects/41416_2009_Article_BF6604851_Fig1_HTML.jpg)
Safety and pharmacokinetics of paclitaxel and the oral mTOR inhibitor everolimus in advanced solid tumours | British Journal of Cancer
![IJMS | Free Full-Text | Prediction of Tacrolimus Exposure by CYP3A5 Genotype and Exposure of Co-Administered Everolimus in Japanese Renal Transplant Recipients IJMS | Free Full-Text | Prediction of Tacrolimus Exposure by CYP3A5 Genotype and Exposure of Co-Administered Everolimus in Japanese Renal Transplant Recipients](https://pub.mdpi-res.com/ijms/ijms-19-00882/article_deploy/html/images/ijms-19-00882-ag.png?1569941125)
IJMS | Free Full-Text | Prediction of Tacrolimus Exposure by CYP3A5 Genotype and Exposure of Co-Administered Everolimus in Japanese Renal Transplant Recipients
![Efficacy and Safety of Everolimus in Combination Therapy, in Patients With HER2-overexpressing Metastatic Breast Cancer Efficacy and Safety of Everolimus in Combination Therapy, in Patients With HER2-overexpressing Metastatic Breast Cancer](https://larvolclin.s3.us-west-2.amazonaws.com/16675465114542993196364bd8f878e2.jpeg)
Efficacy and Safety of Everolimus in Combination Therapy, in Patients With HER2-overexpressing Metastatic Breast Cancer
![Recommendations for the use of everolimus in de novo kidney transplantation: False beliefs, myths and realities - ScienceDirect Recommendations for the use of everolimus in de novo kidney transplantation: False beliefs, myths and realities - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S2013251417300883-gr1.jpg)
Recommendations for the use of everolimus in de novo kidney transplantation: False beliefs, myths and realities - ScienceDirect
![Progression-free survival, (a) by everolimus dose. Progression-free... | Download Scientific Diagram Progression-free survival, (a) by everolimus dose. Progression-free... | Download Scientific Diagram](https://www.researchgate.net/publication/338960099/figure/fig3/AS:864813265727491@1583198958336/Progression-free-survival-a-by-everolimus-dose-Progression-free-survival-b-by.jpg)
Progression-free survival, (a) by everolimus dose. Progression-free... | Download Scientific Diagram
![Frontiers | Low-Dose Everolimus Maintenance Therapy for Renal Angiomyolipoma Associated With Tuberous Sclerosis Complex Frontiers | Low-Dose Everolimus Maintenance Therapy for Renal Angiomyolipoma Associated With Tuberous Sclerosis Complex](https://www.frontiersin.org/files/Articles/744050/fmed-08-744050-HTML/image_m/fmed-08-744050-g001.jpg)
Frontiers | Low-Dose Everolimus Maintenance Therapy for Renal Angiomyolipoma Associated With Tuberous Sclerosis Complex
![Initial dose and dose adjustments of everolimus and axitinib as second... | Download Scientific Diagram Initial dose and dose adjustments of everolimus and axitinib as second... | Download Scientific Diagram](https://www.researchgate.net/publication/286766440/figure/tbl1/AS:669110786600982@1536539851854/Initial-dose-and-dose-adjustments-of-everolimus-and-axitinib-as-second-targeted-therapy.png)